Clinical Implication of CDH1 Mutations in Genetic Testing for Diffuse Gastric Cancer Patients
Oncology · 2024
DOI: 10.1159/000533774 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Oncology, 2024. Verfasst von Giovanni Corso und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
The objective of this study was to reclassify published germline CDH1 variants identified in gastric cancer (GC) in accordance with the latest ClinVar definition and to correlate their pathogenicity with the established international clinical criteria for genetic testing.
Methods
The relevant literature dating from 1998 to 2019 was systematically searched for data on CDH1 germline mutations in accord with PRISMA guidelines. The collected variants were classified according to the latest ClinVar definition into the following classes: benign (B), likely benign (LB), pathogenic (P), likely pathogenic (LP), and variant of unknown significance (VUS). The McNemar test was used to compare the adequacy of current versus previous International GC Linkage Consortium (IGCLC) criteria.
Results
We reclassified a total of 247 CDH1 variants, and we identified that about 70% of B/LB variant carriers were not fulfilling the defined clinical criteria. Instead, all P/LP variants (100%) were associated with the hereditary diffuse gastric cancer (HDGC) phenotype fulfilling the 2020 ILGCC criteria, with a significant improvement (p = 0.025) compared to previous version.
Conclusions
We conclude that germline CDH1 genetic testing is indicated only in families meeting the clinical criteria for the HDGC syndrome. This observation suggests that clinical phenotypes that do not clearly fulfill these criteria should not be considered for CDH1 genetic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- European Cancer Prevention Organization (ECP), Milan, Italy.
- Division of Endoscopy, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
- Division of Urology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
- Division of Pathology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Zitieren
APA
Corso, G., Trovato, C. M., Petitto, S., Girardi, A., De Scalzi, A. M., Bianchi, B., Magnoni, F., Cioffi, A., Galimberti, V., Veronesi, P., Mazzarol, G., & Maisonneuve, P. (2024). Clinical Implication of CDH1 Mutations in Genetic Testing for Diffuse Gastric Cancer Patients. Oncology. https://doi.org/10.1159/000533774
Vancouver
Corso G, Trovato CM, Petitto S, Girardi A, De Scalzi AM, Bianchi B, et al. Clinical Implication of CDH1 Mutations in Genetic Testing for Diffuse Gastric Cancer Patients. Oncology. 2024. doi:10.1159/000533774
BibTeX
@article{Corso2024,
author = {Corso, Giovanni and Trovato, Cristina Maria and Petitto, Salvatore and Girardi, Antonia and De Scalzi, Alessandra Margherita and Bianchi, Beatrice and Magnoni, Francesca and Cioffi, Antonio and Galimberti, Viviana and Veronesi, Paolo and Mazzarol, Giovanni and Maisonneuve, Patrick},
title = {Clinical Implication of CDH1 Mutations in Genetic Testing for Diffuse Gastric Cancer Patients},
journal = {Oncology},
year = {2024},
doi = {10.1159/000533774}
}
EUVIMED